Cargando…

Early-Phase Adverse Effects and Management of Liposomal Amikacin Inhalation for Refractory Mycobacterium avium Complex Lung Disease in Real-World Settings

PURPOSE: Amikacin liposome inhalation suspension (ALIS), which efficiently allows amikacin to reach the pulmonary periphery for effect while minimising systemic adverse effects, was recently approved for treating Mycobacterium avium complex (MAC) infections. The international Phase 3 open-label clin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Morita, Atsuho, Namkoong, Ho, Yagi, Kazuma, Asakura, Takanori, Hosoya, Makoto, Tanaka, Hiromu, Lee, Ho, Ogawa, Takunori, Kusumoto, Tatsuya, Azekawa, Shuhei, Nakagawara, Kensuke, Kamata, Hirofumi, Ishii, Makoto, Fukunaga, Koichi, Ozawa, Hiroyuki, Hasegawa, Naoki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Case Series
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9342928/ https://www.ncbi.nlm.nih.gov/pubmed/35924016 http://dx.doi.org/10.2147/IDR.S373783

Ejemplares similares

Laryngitis after inhalation of liposomal amikacin
por: Morita, Atsuho, et al.
Publicado: (2022)

Longitudinal significance of six-minute walk test in patients with nontuberculous mycobacterial pulmonary disease: an observational study
por: Morita, Atsuho, et al.
Publicado: (2023)

Nasopharyngeal Mycobacterium abscessus Infection: A Case Report and Literature Review
por: Kaji, Masanori, et al.
Publicado: (2023)

Osteoporosis in nontuberculous mycobacterial pulmonary disease: a cross-sectional study
por: Tanaka, Hiromu, et al.
Publicado: (2022)

Association between six-minute walk test parameters and the health-related quality of life in patients with pulmonary Mycobacterium avium complex disease
por: Yagi, Kazuma, et al.
Publicado: (2018)

Sitafloxacin-Containing Regimen for the Treatment of Refractory Mycobacterium avium Complex Lung Disease
por: Asakura, Takanori, et al.
Publicado: (2019)

Impact of chronic Pseudomonas aeruginosa infection on health-related quality of life in Mycobacterium avium complex lung disease
por: Kamata, Hirofumi, et al.
Publicado: (2017)

Characteristics and clinical effectiveness of COVID-19 vaccination in hospitalized patients in Omicron-dominated epidemic wave – a nationwide study in Japan
por: Tanaka, Hiromu, et al.
Publicado: (2023)

Development of Rheumatoid Arthritis in Cavitary Mycobacterium avium Pulmonary Disease: A Case Report of Successful Treatment with CTLA4-Ig (Abatacept)
por: Tanaka, Hiromu, et al.
Publicado: (2022)

Amikacin liposome and Mycobacterium avium complex: A systematic review
por: Zangiabadian, Moein, et al.
Publicado: (2022)

Serum KL-6 levels predict clinical outcomes and are associated with MUC1 polymorphism in Japanese patients with COVID-19
por: Azekawa, Shuhei, et al.
Publicado: (2023)

Clinical efficacy and safety of multidrug therapy including thrice weekly intravenous amikacin administration for Mycobacterium abscessus pulmonary disease in outpatient settings: a case series
por: Namkoong, Ho, et al.
Publicado: (2016)

The efficacy, safety, and feasibility of inhaled amikacin for the treatment of difficult-to-treat non-tuberculous mycobacterial lung diseases
por: Yagi, Kazuma, et al.
Publicado: (2017)

Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
por: Shirley, Matt
Publicado: (2019)

Thymoma-associated T-cell immunodeficiency after radiotherapy: A case report
por: Nakagawara, Kensuke, et al.
Publicado: (2021)

Correction to: Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
por: Shirley, Matt
Publicado: (2019)

Immune reconstitution inflammatory syndrome due to Mycobacterium avium complex successfully followed up using (18) F-fluorodeoxyglucose positron emission tomography-computed tomography in a patient with human immunodeficiency virus infection: A case report
por: Namkoong, Ho, et al.
Publicado: (2015)

Impact of upper and lower respiratory symptoms on COVID-19 outcomes: a multicenter retrospective cohort study
por: Nakagawara, Kensuke, et al.
Publicado: (2022)

Successful resumption of tocilizumab for rheumatoid arthritis after resection of a pulmonary Mycobacterium avium complex lesion: a case report
por: Namkoong, Ho, et al.
Publicado: (2015)

Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
por: Hoy, Sheridan M.
Publicado: (2021)

Amikacin liposome inhalation suspension clinical benefit–risk assessment for refractory Mycobacterium avium complex lung disease
por: Marras, Theodore K., et al.
Publicado: (2022)

Health-related quality of life is inversely correlated with C-reactive protein and age in Mycobacterium avium complex lung disease: a cross-sectional analysis of 235 patients
por: Asakura, Takanori, et al.
Publicado: (2015)

Characteristics of hospitalized patients with COVID-19 during the first to fifth waves of infection: a report from the Japan COVID-19 Task Force
por: Lee, Ho, et al.
Publicado: (2022)

Correction to: Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
por: Hoy, Sheridan M.
Publicado: (2021)

805. Amikacin Liposome Inhalation Suspension (ALIS) Add-on Therapy for Refractory Mycobacterium avium Complex (MAC) Lung Disease: Effect of In Vitro Amikacin Susceptibility on Sputum Culture Conversion
por: Brown-Elliott, Barbara A, et al.
Publicado: (2018)

Liposomal Amikacin Inhalation Suspension-induced Pneumonitis
por: Kidogawa, Moe, et al.
Publicado: (2022)

Amikacin Liposome Inhalation Suspension for Mycobacterium avium Complex Lung Disease: A 12-Month Open-Label Extension Clinical Trial
por: Winthrop, Kevin L., et al.
Publicado: (2021)

Clinical clustering with prognostic implications in Japanese COVID-19 patients: report from Japan COVID-19 Task Force, a nation-wide consortium to investigate COVID-19 host genetics
por: Otake, Shiro, et al.
Publicado: (2022)

U-shaped association between abnormal serum uric acid levels and COVID-19 severity: reports from the Japan COVID-19 Task Force
por: Fukushima, Takahiro, et al.
Publicado: (2022)

Effects of mild obesity on outcomes in Japanese patients with COVID-19: a nationwide consortium to investigate COVID-19 host genetics
por: Lee, Ho, et al.
Publicado: (2022)

Co-infection with SARS-CoV-2 and influenza A virus
por: Azekawa, Shuhei, et al.
Publicado: (2020)

Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series
por: Davis, Kala K, et al.
Publicado: (2007)

Analysis of adverse drug events in pulmonary Mycobacterium avium complex disease using spontaneous reporting system
por: Ozawa, Takuya, et al.
Publicado: (2022)

Levels of Soluble Receptor for Advanced Glycation End Products in Bronchoalveolar Lavage Fluid in Patients with Various Inflammatory Lung Diseases
por: Kamo, Tetsuro, et al.
Publicado: (2016)

Prognostic values of the Berlin definition criteria, blood lactate level, and fibroproliferative changes on high-resolution computed tomography in ARDS patients
por: Kamo, Tetsuro, et al.
Publicado: (2019)

Amikacin Liposome Inhalation Suspension (ALIS) Penetrates Non-tuberculous Mycobacterial Biofilms and Enhances Amikacin Uptake Into Macrophages
por: Zhang, Jimin, et al.
Publicado: (2018)

Longitudinal long COVID symptoms in Japanese patients after COVID-19 vaccinations
por: Nakagawara, Kensuke, et al.
Publicado: (2023)

Dry pleurisy complicating solitary pulmonary nodules caused by Mycobacterium avium: a case report
por: Asakura, Takanori, et al.
Publicado: (2015)

Retrospective evaluation of natural course in mild cases of Mycobacterium avium complex pulmonary disease
por: Kimizuka, Yoshifumi, et al.
Publicado: (2019)

Clarithromycin expands CD11b(+)Gr-1(+) cells via the STAT3/Bv8 axis to ameliorate lethal endotoxic shock and post-influenza bacterial pneumonia
por: Namkoong, Ho, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_861g3idcu5onjq6c6b4rjecqf6